Back
 OALibJ  Vol.2 No.6 , June 2015
Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa
Abstract: Background: Viral Load (VL), CD4 T cells count and clinical signs are significant parameters for the decision of starting ARV Treatment (ART). The aim of this study is to determine the Viral Load profile of eligible patients on treatment in the centers according to the algorithm used in Kinshasa and the DRC. Methodology: Our sample consisted of 153 HIV-positive patients naive of ART. All patients aged over 18 years were included in the study without gender discrimination. The determination of the VL was made at the laboratory of Molecular Biology of the Faculty of Medicine of the University of Kinshasa using a previously described technique. Results: Of the 153 patients included in the study, 92 (60.1%) were women. The age of the patients was in the range 18 - 65 years with a mean of 37 years. Most patients (91.5%) were clinical stage 3, while the rest (8.5%) were clinical stage 4 for HIV infection. The rates of CD4 T lymphocytes were between 8 and 915 cells/mm3 with a median value of 180 cells/mm3. Seventy nine patients (86.8%) had CD4 count below 500 cells/mm3. The median VL of patients is 5.68 log10 RNA copies/ml. The minimum and maximum values are respectively 0.37 and 7.95 log10 RNA copies/ml. Conclusion: The majority of patients (63.4%) in Kinshasa begin antiretroviral treatment with a poor prognosis. The Viral loads are usually very high in these patients and CD4 quite collapsed. Indeed, the median value of CD4 for the patients is 180 cells/mm3 for the population, while the mean value of Viral Load is 5.48 log10 RNA copies/ml.
Cite this paper: Kamangu, E. , Bulanda, B. , Bongenia, B. , Botomwito, H. , Mvumbi, G. , Mol, P. , Vaira, D. , Hayette, M. and Kalala, R. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, 1-5. doi: 10.4236/oalib.1101564.
References

[1]   Programme National de Lutte contre le VIH/SIDA et les Infections Sexuellement Transmissible (PNLS), Ministère de la Santé Publique, République Démocratique du Congo (RDC). Rapport Annuel. 2009 à 2012.

[2]   Programme National de Lutte contre le VIH/SIDA et les Infections Sexuellement Transmissible (PNLS), Ministère de la Santé Publique, République Démocratique du Congo (RDC). Guide National de Prise en Charge de l’Infection à VIH en RDC. Version révisé 2013.

[3]   World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents, Recommendations for a Public Health Approach. Revision 2010.
http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf

[4]   Ingole, N.A., Kukreja, S.M. and Mehta, P.R. (2011) Role of HIV-1 Viral Load in Initiating Antiretroviral Therapy. World Journal of AIDS, 1, 149-154.
http://dx.doi.org/10.4236/wja.2011.14022

[5]   Kamangu, N.E., Kawila, M.E., Mukumbi, H. and Mvumbi, L.G. (2012) Estimated Rates of Treatment Failure in First-Line Antiretroviral Treatment in Kinshasa: Case of the ACS AMO-Congo. International Journal of Collaborative Research on Internal Medicine and Public Health (IJCRIMPH), 4, 885-891.

[6]   Calmy, A., Ford, N., Hirschel, B., Reynolds, S.J., Lynen, L., Goemaere, E., De la Vega, F.G., Perrin, L. and Rodriguez, W. (2007) HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary? Clinical Infectious Diseases, 44, 128-134.
http://dx.doi.org/10.1086/510073

[7]   Kamangu, N.E., Kalala, N.H. and Mesia, K.G. (2012) Profile of Antiretroviral Treatment Centers in Kinshasa, Democratic Republic of Congo [Poster 388]. Proceedings of the 1st International African Society of Laboratory Medicine (ASLM) Conference, Cape Town, 1-7 December 2012, 377.

[8]   Kamangu, N.E., Adawaye, C., Boreux, R., Kalala, L.R., Mvumbi, L.G., Vaira, D. and Hayette, M.P. (2014) Mise en place d’une PCR Quantitative Temps Réel pour la détermination de la Charge Virale VIH à Kinshasa. Journal de RechercheBioMédicale, 1, 7-12.

[9]   Kamangu, N.E., Chatte, A., Boreux, R., Kalala, L.R., Mvumbi, L.G., De Mol, P., Vaira, D. and Hayette, M.P. (2014) Implementation of an In-House Quantitative Real-Time PCR for Determination of HIV Viral Load in Kinshasa. Open Access Library Journal, 1, e855.
http://dx.doi.org/10.4236/oalib.1100855

[10]   Desclaux, A. and Desgrées du Lou, A. (2006) Les Femmes Africaines face à l’épidémie du SIDA. Population etSociétés, 428, 1-4.

[11]   Karier, R. and Marissa, Y. (2009) Renforcement de l’intégration des services de planification familiale et de traitement du VIH. PRB USAID.

[12]   Kamangu, N.E., Situakibanza, N.H., Mvumbi, L.G., Kakudji, I.L., Tshienda, T.D. and Mesia, K.G. (2012) Infections Opportunistes chez les Personnes Vivant avec le VIH suivi à l’Hôpital Militaire de Référence de Kinshasa (Camp Kokolo). Revue Congolaise des Sciences, 1, 66-76.

[13]   ONUSIDA (2006) Rapport sur l’épidémiologie Mondiale du SIDA. ONUSIDA, Genève, 3-4.

[14]   Wateba, I.N., Patassi, A.A., Balaka, A. and Tidjani, O. (2013) Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé, Togo. World Journal of AIDS, 3, 364-366.
http://dx.doi.org/10.4236/wja.2013.34047

[15]   Egger, M., May, M. and Chêne, G. (2002) Prognosis of HIV-1-Infected Patients Starting Highly Active Therapy: A Collaborative Analysis of Prospective Studies. The Lancet, 360, 119-129.
http://dx.doi.org/10.1016/S0140-6736(02)09411-4

[16]   Phair, J.P., Mellors, J.W., Detels, R., Margolick, J.B. and Munoz, A. (2002) Virologic and Immunologic Values Allowing Safe Deferral of Antiretroviral Therapy. AIDS, 16, 2455-2459.
http://dx.doi.org/10.1097/00002030-200212060-00011

 
 
Top